{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:10:47Z","timestamp":1782274247033,"version":"3.54.5"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Insmed Incorporated"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.prostaglandins.2020.106486","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T04:39:46Z","timestamp":1601527186000},"page":"106486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts"],"prefix":"10.1016","volume":"152","author":[{"given":"Michel R.","family":"Corboz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Salvail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"LaSala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Salvail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2020.106486_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0031-6997(25)06759-6","article-title":"Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin","volume":"30","author":"Moncada","year":"1978","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0030","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/S0021-9258(20)81984-X","article-title":"Bimodal distribution of the prostaglandin I2 synthase antigen in smooth muscle cells","volume":"258","author":"Smith","year":"1983","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0035","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1164\/ajrccm.164.2.2010150","article-title":"Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling","volume":"164","author":"Hoshikawa","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0045","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.200710-1519OC","article-title":"Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension","volume":"178","author":"Lai","year":"2008","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0055","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1100\/tsw.2007.184","article-title":"Prostanoid receptors in the human vascular wall","volume":"7","author":"Norel","year":"2007","journal-title":"Sci. World J."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"Kuwano","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.13305","article-title":"The prostacyclin analogue treprostinil in the treatement of pulmonary arterial hypertension","volume":"126","author":"Pedersen","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/jpet.117.242099","article-title":"Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug","volume":"363","author":"Corboz","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostaglandin Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.bjp.0706841","article-title":"Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations","volume":"149","author":"Jones","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0085","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1476-5381.2009.00317.x","article-title":"Prostanoid receptor antagonists: development strategies and therapeutic applications","volume":"158","author":"Jones","year":"2009","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0090","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist","volume":"164","author":"af Forselles","year":"2011","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0095","first-page":"794","article-title":"PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors, Br. J","volume":"168","author":"S\u00e4fholm","year":"2013","journal-title":"Pharmacol ."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0100","first-page":"7505","article-title":"Antifibrotic effects of noscapine through activation of prostaglandin E2 receptors and protein kinase A, J. Biol","volume":"289","author":"Kach","year":"2014","journal-title":"Chem ."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2018.01.012","article-title":"Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats","volume":"49","author":"Corboz","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0110","article-title":"Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice","volume":"46","author":"Manitsopoulos","year":"2015","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205195","article-title":"Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells","volume":"13","author":"Lambers","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ppul.24190","article-title":"Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension","volume":"54","author":"Bacha","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.112.197152","article-title":"Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery","volume":"343","author":"Morrison","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2013.07.003","article-title":"Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins","volume":"106","author":"Orie","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2013.07.001","article-title":"A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor","volume":"107","author":"Benyahia","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2016.11.057","volume":"795","author":"Fuchikami","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.prostaglandins.2015.09.002","article-title":"Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents","volume":"121","author":"Benyahia","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0150","doi-asserted-by":"crossref","first-page":"L555","DOI":"10.1152\/ajplung.2001.280.3.L555","article-title":"17beta-estradiol increases nitric oxide-dependent dilation in rat pulmonary arteries and thoracic aorta","volume":"280","author":"Gonzales","year":"2001","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1152\/physiolgenomics.00136.2007","article-title":"Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension","volume":"32","author":"Tang","year":"2008","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cardiores.2005.12.020","article-title":"Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases","volume":"70","author":"Alfranca","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0170","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3389\/fphar.2018.01518","article-title":"Mechanism of beraprost effects on pulmonary hypertension: contribution of cross-binding to PGE2 receptor 4 and modulation of O2 sensitive voltage-gated K+ channels","volume":"9","author":"Fan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0175","doi-asserted-by":"crossref","first-page":"23258","DOI":"10.1074\/jbc.273.36.23258","article-title":"Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c","volume":"273","author":"Smyth","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1465-9921-8-4","article-title":"Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs","volume":"8","author":"Schermuly","year":"2007","journal-title":"Respir. Res."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0185","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bjp.0702393","article-title":"Prostanoid receptors involved in the relaxation of human pulmonary vessels","volume":"126","author":"Walch","year":"1999","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0190","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0195","doi-asserted-by":"crossref","first-page":"L213","DOI":"10.1152\/ajplung.00103.2004","article-title":"Role of veins in regulation of pulmonary circulation","volume":"288","author":"Gao","year":"2005","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-5381.1994.tb16997.x","article-title":"Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery","volume":"113","author":"Qian","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bcp.2019.05.026","article-title":"Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension","volume":"166","author":"Shen","year":"2019","journal-title":"J. Biochem. Pharmacol. Res."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0210","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1172\/JCI77656","article-title":"EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho\/TGF-\u03b21 signaling","volume":"125","author":"Lu","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19082372","article-title":"Prostanoid EP2 receptors are up-regulated in human pulmonary arterial hypertension: a key anti-proliferative target for treprostinil in smooth muscle cells","volume":"19","author":"Patel","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pupt.2018.02.002","article-title":"Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil","volume":"49","author":"Chapman","year":"2018","journal-title":"Pulm. Pharmacol. Therap."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0225","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1378\/chest.15-1029","article-title":"Prostanoids in asthma and COPD, actions, dysregulation, and therapeutic opportunities","volume":"148","author":"Zaslona","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1254\/jphs.12275FP","article-title":"Prostaglandin D2 inhibits collagen secretion from lung fibroblasts by activating the DP receptor","volume":"121","author":"Ayabe","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0235","doi-asserted-by":"crossref","first-page":"L405","DOI":"10.1152\/ajplung.00232.2006","article-title":"Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling","volume":"292","author":"Huang","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-19294-1","article-title":"Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation","volume":"8","author":"Lambers","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1165\/rcmb.2002-0243OC","article-title":"Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation","volume":"29","author":"Kolodsick","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2014-0468OC","article-title":"Reversal of the transcriptome by prostaglandin E2 during myofibroblast dedifferentiation","volume":"54","author":"Wettlaufer","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0255","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1165\/rcmb.2012-0262OC","article-title":"Reversal of myofibroblast differentiation by prostaglandin E(2)","volume":"48","author":"Garrison","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0260","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/ATVBAHA.111.226142","article-title":"Targeted disruption of the prostaglandin E2 E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice","volume":"31","author":"Zhu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0265","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.4049\/jimmunol.174.9.5644","article-title":"Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2","volume":"174","author":"Moore","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0270","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1165\/rcmb.2011-0025RT","article-title":"Prostaglandin E2 and the pathogenesis of pulmonary fibrosis","volume":"45","author":"Bozyk","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0275","doi-asserted-by":"crossref","first-page":"L645","DOI":"10.1152\/ajplung.00176.2011","article-title":"Prostaglandin E\u2082 protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction","volume":"301","author":"Dackor","year":"2011","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1577-0","article-title":"Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts","volume":"20","author":"Cutolo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0285","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/mol.58.6.1279","article-title":"Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration","volume":"58","author":"Desai","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0290","article-title":"No evidence of desensitization to repeat dosing with treprostinil palmitil inhalation suspension (TPIS) for 32-consecutive days in hypoxia-challenged telemetered rats","author":"Chapman","year":"2020","journal-title":"ERS"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0295","first-page":"A2094","article-title":"Determination of the prostanoid receptor subtype involved in treprostinil-induced cough in guinea pigs","volume":"201","author":"Corboz","year":"2020","journal-title":"Am. J. Res. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0300","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/rccm.200903-0388OC","article-title":"Prostaglandin E2 mediates cough via EP3 receptor activation: implications for future disease therapy","volume":"180","author":"Maher","year":"2009","journal-title":"Am. J. Res. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0305","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1183\/09031936.00061614","article-title":"Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events","volume":"45","author":"Maher","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0310","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0315","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCRESAHA.109.209940","article-title":"Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo","volume":"107","author":"Yang","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0320","series-title":"Molecular Mechanisms of Congestive Heart Disease and Pulmonary Hypertension","first-page":"31","article-title":"Diverse pharmacology of prostacyclin mimetics: implications for pulmonary hypertension","author":"Clapp","year":"2020"},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pharmthera.2013.03.006","article-title":"E-type prostanoid receptor 4 (EP4) in disease and therapy","volume":"138","author":"Konya","year":"2013","journal-title":"Pharmacol. Therap."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0330","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/ATVBAHA.110.216374","article-title":"The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation","volume":"30","author":"Philipose","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106486_bib0335","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09537101003718065","article-title":"The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function","volume":"21","author":"Iy\u00fa","year":"2010","journal-title":"Platelets"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:54:58Z","timestamp":1762365298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882320300794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":67,"alternative-id":["S1098882320300794"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106486","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106486"}}